Catalyst Biosciences, Inc. — Form 10-Q Summary
Period: Quarter and nine months ended September 30, 2016; filed November 3, 2016. The request metadata names Gyre Therapeutics, Inc., but the supplied filing is for Catalyst Biosciences, Inc. Investors should verify the issuer and filing identity.
Business context and outlook
Catalyst is a clinical-stage biotechnology company focused on hemostasis, including hemophilia and surgical bleeding. It reported no product sales; contract revenue came from collaboration payments. Its lead candidate, marzeptacog alfa (activated), completed an intravenous Phase 1 trial, and the company expected to begin a subcutaneous prophylaxis trial in 2017. CB 2679d/ISU304 completed advanced preclinical IND-enabling work, with a subcutaneous trial expected to start in the first quarter of 2017. Management prioritized these programs and delayed further Factor Xa research while exploring licensing for anti-complement programs.
Financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Contract revenue | $0.109 million | $0.109 million | $0.328 million | $1.641 million |
| Research and development expense | $3.396 million | $1.486 million | $8.443 million | $4.192 million |
| General and administrative expense | $2.425 million | $2.508 million | $7.083 million | $6.567 million |
| Operating loss | $(5.712) million | $(3.885) million | $(15.198) million | $(9.118) million |
| Net loss | $(4.771) million | $(5.051) million | $(13.195) million | $(9.632) million |
| Net loss per share | $(0.40) | $(0.93) | $(1.14) | $(4.65) |
Gross margin is not presented. Revenue was immaterial relative to operating expenses, and the company had no commercial product revenue. Q3 net loss narrowed modestly, despite higher operating expenses, mainly because interest and other income rose and 2015 included $1.439 million of interest expense. Nine-month net loss widened 37%, reflecting higher operating expenses and lower contract revenue. R&D expense increased 101% for the nine-month period, primarily from marzeptacog manufacturing, personnel, and preclinical and laboratory costs. Revenue fell 80% year over year, principally because Pfizer terminated its collaboration in June 2015; ISU Abxis accounted for all 2016 contract revenue.
Cash, liquidity, debt and cash flow
- At September 30, 2016, cash and cash equivalents were $9.317 million, short-term investments $10.208 million, and restricted cash $29.844 million current plus $0.125 million noncurrent. Unrestricted cash, cash equivalents, and short-term investments totaled approximately $19.5 million.
- Total assets were $51.616 million, total liabilities $32.012 million, and stockholders’ equity $19.604 million. Accumulated deficit was $144.232 million.
- Redeemable convertible notes were $29.667 million at quarter-end. The notes are non-interest-bearing, secured, and backed by restricted escrow funds; holders may redeem or convert them, and remaining notes mature February 19, 2018. Since the merger, $7.1 million had been redeemed and $0.2 million converted; $4.1 million was redeemed during the first nine months of 2016. The filing reports no other debt obligations in 2016.
- For the first nine months, operating cash used was $13.495 million, investing cash used $7.149 million, and financing cash provided $0.865 million; cash and cash equivalents declined $19.779 million. Investing outflows primarily reflected purchases of investments, offset by maturities.
- Management believed existing capital resources would fund projected operating requirements for at least 12 months, while cautioning that estimates could prove wrong. The company also cited possible future equity or debt financing, asset sales, licensing, collaborations, or partnerships; additional capital was not assured.
Material developments, risks and contingencies
- In September, the company announced a 10-person workforce reduction, approximately 50% of staff, to reallocate resources to hemostasis programs. Estimated severance and related costs were about $1.0 million; approximately $0.7 million had been paid by quarter-end, with the remainder expected to be paid by year-end.
- A manufacturing services agreement with CMC ICOS Biologics provided for $3.8 million in payments, subject to work stages; $3.5 million remained payable at September 30. The contractual-obligations table included $3.563 million due in less than one year. Operating lease obligations totaled $1.051 million.
- In July, the company sold certain neural nicotinic receptor assets for approximately $1.0 million upfront plus potential milestones and royalties, recognizing $0.804 million net in other income in the period. After quarter-end, it agreed to sell TC-6499 for approximately $0.8 million upfront plus potential milestones and royalties.
- The derivative liability associated with the redeemable notes fell from $1.156 million at year-end 2015 to $0.028 million at September 30, 2016; fair-value changes contributed to reported other income. Such noncash gains make reported net loss less directly comparable with operating performance.
- Key risks include clinical failure or delays, uncertain efficacy and safety of planned subcutaneous dosing, possible immune responses, competition, and the need for additional financing. One participant in the marzeptacog Phase 1 study had a weak, transient, non-neutralizing antibody result; the filing says later review suggested it might be a false positive. No neutralizing antibodies were observed in that trial.
- The company disclosed no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of September 30, 2016.
Most important facts to verify
- Confirm the filing issuer: the supplied document is Catalyst Biosciences, Inc., not Gyre Therapeutics, Inc.
- Check the composition and availability of liquidity, particularly the $29.844 million of restricted cash pledged in connection with the notes.
- Track cash burn against management’s stated 12-month funding estimate and assess whether additional financing will be needed.
- Monitor trial starts and results for the planned subcutaneous programs, manufacturing readiness, and the company’s ability to fund the CMC commitments.
- Assess recurring operating costs separately from one-time restructuring charges, asset-sale proceeds, and derivative fair-value gains.
- Verify note redemptions, conversions, maturity terms, and potential dilution from outstanding options, warrants, and convertible notes.